Source: NASDAQ Stocks / 10 May 2025 04:18:12 America/New_York
Fintel reports that on May 9, 2025, JMP Securities downgraded their outlook for Iovance Biotherapeutics (LSE:0JDK) from Market Outperform to Market Perform.
https://www.nasdaq.com/articles/jmp-securities-downgrades-iovance-biotherapeutics-lse-0jdk